Jazz Pharmaceuticals’ Board of Directors has unanimously selected Renee Gala, Jazz’s President and Chief Operating Officer, as President and Chief Executive Officer, effective August 11, 2025.
Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key narcolepsy drug Xyrem with a cool $145 million settlement.
Early this week, the company inked a settlement agreement with a group of indirect purchaser plaintiffs who took the company to court over an alleged "pay-for-delay" arrangement to thwart generic competition to Xyrem. In 2020, the allegations were consolidated into a multidistrict litigation (MDL) case in a North Carolina federal court.
Jazz Pharmaceuticals said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem.
Before Jazz Pharmaceuticals inked a $935 million deal for Chimerix earlier this month, the biotech had been in talks with six other pharmas and one biotech about several different potential offers.
Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline.
Buying Chimerix will give Jazz control of the brain cancer drug candidate dordaviprone.
Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought investors’ attention to the company’s appetite in dealmaking.
“We plan to further diversify our commercial and pipeline portfolios through strategic corporate development, which remains a key focus for Jazz,” Cozadd said on the call Tuesday.
Bruce Cozadd, who co-founded the company two decades ago, will step down once a successor is found. Jazz aims to complete its search within one year.
A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate Enhertu.
Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer (ES-SCLC).
Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone with used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo, Jazz said Tuesday.